Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 16/20 | 0.67 |
| ▸ | CA1 | P00915 | 15/20 | 0.67 |
| ▸ | CA2 | P00918 | 15/20 | 0.67 |
| ▸ | CA12 | O43570 | 7/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | HTR3A | P46098 | 2/20 | 0.57 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17753778 | 0.94 | CA9 (0.66) | CA9CA1CA2CA12CA14 | |
| SCHEMBL24519189 | 0.91 | CA9 (0.56) | CA9CA1CA2CA12CA14 | |
| SCHEMBL24606377 | 0.89 | CA9 (0.69) | CA9CA1CA2CA12CA14 | |
| SCHEMBL24444501 | 0.88 | CA9 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13915130 | 0.87 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12678101 | 0.86 | CA9 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13219607 | 0.86 | CA1 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13815114 | 0.86 | CA1 (0.71) | CA9CA1CA2CA12CA14 | |
| SCHEMBL19426705 | 0.85 | CA9 (0.71) | CA9CA1CA2CA12CA14 | |
| SCHEMBL20622624 | 0.85 | CA9 (0.75) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015936-A1 | METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE | NBE-THERAPEUTICS AG (CH) | 2021-01-21 | — | — | US | disclosed |
| US-10864277-B2 | Method of producing an immunoligand/payload conjugate | NBE THERAPEUTICS AG (CH) | 2020-12-15 | — | — | US | disclosed |
| US-20190262461-A1 | METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE | NBE THERAPEUTICS AG (CH) | 2019-08-29 | — | — | US | disclosed |
| US-9872923-B2 | Method of producing an immunoligand/payload conjugate | NBE THERAPEUTICS AG (CH) | 2018-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262461-A1 | METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE | ENGASE, ENPEP, DNPEP | CA9 826/4885CA1 1293/4885CA2 2405/4885 |
| US-10864277-B2 | Method of producing an immunoligand/payload conjugate | DNPEP, FOLH1, ENGASE | CA9 525/4885CA1 873/4885CA2 2403/4885 |
| US-20210015936-A1 | METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE | DNPEP, FOLH1, ENGASE | CA9 525/4885CA1 873/4885CA2 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.